Letermovir

Drug Profile

Letermovir

Alternative Names: AIC-001; AIC-090027; AIC-246; BAY-73-6327; MK-8228

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer
  • Developer Merck & Co
  • Class Acetates; Antivirals; Fluorobenzenes; Phenyl ethers; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for Letermovir in USA (Merck Annual report 2016)
  • 26 Feb 2017 Merck announces intention to submit NDA to USA and MAA to European Union in 2017
  • 26 Feb 2017 Safety and adverse events data from a phase III trial in Cytomegalovirus infection released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top